Literature DB >> 26280320

Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma.

F Tunca1, I C Sormaz2, Y Iscan3, Y G Senyurek2, T Terzioglu2.   

Abstract

PURPOSE: To compare the histopathological features and the outcomes of the follicular variant and classical variant of papillary thyroid carcinoma. MATERIAL AND THE
METHODS: Demographic data, histopathological features (tumor size, thyroid capsule invasion, extrathyroidal extension, vascular invasion and multicentricity), lymph node metastasis, local recurrence, distant metastasis and mortality during the follow-up of 258 C-PTC and 153 FVPTC patients who underwent total thyroidectomy were compared. The dynamic risk assessment system was used to refine postoperative risk estimates based on the assessment of response to initial treatment.
RESULTS: The demographic data showed no significant difference between the two groups. The mean tumor size showed no significant difference between the two groups. The rate of thyroid capsule invasion, extrathyroidal extension, and lymph node metastasis was significantly higher in C-PTC than in FVPTC group, whereas multicentricity and bilobar involvement were significantly higher in FVPTC group than in C-PTC group. Central lymph node metastasis was significantly more frequent in patients with C-PTC than in those with FVPTC (p < 0.0001). Local recurrence was found in 22 (5.3 %) patients overall and was significantly more common in C-PTC group than in FVPTC group. In patients ≥45 years, the local recurrence rate was significantly higher in patients with CPTC than in those with FVPTC. The local recurrence rate in patients <45 years was not significantly different between the two groups of patients. The multicentricity rate was significantly higher in the FVPTC group for both age groups. Dynamic risk assessment showed that the rate of intermediate- and high-risk groups showed no significant difference between C-PTC and FVPTC patients but the rate of low risk patients was higher in FVPTC group than in C-PTC group (p = 0.04). The recurrence rate in low-risk group was found higher in C-PTC compared to FVPTC patients (4.7 vs. 0.7 %, p = 0.04, respectively). The recurrence rate showed no significant difference in both intermediate- and high-risk groups in C-PTC and FVPTC patients. During the follow-up, the rate of distant metastasis and disease-specific mortality was not significantly different between the two groups (p = 0.25).
CONCLUSION: FVPTC is a common subtype of PTC and has a higher rate of multicentricity with bilobar involvement. Although aggressive histopathologic features, such as thyroid capsule invasion, extrathyroidal extension, and lymph node metastasis, are significantly more frequent in CPTC than in FVPTC, the long-term outcome is similar in both subtypes after appropriate initial surgery and postoperative RAI ablation treatment.

Entities:  

Keywords:  Classic and follicular variant papillary thyroid carcinoma; Histopathological features; Prognosis

Mesh:

Year:  2015        PMID: 26280320     DOI: 10.1007/s40618-015-0376-6

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

1.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

2.  The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors:  Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

3.  Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma.

Authors:  Laura Falvo; Antonio Catania; Vito D'Andrea; Antonella Marzullo; Maria Cristina Giustiniani; Enrico De Antoni
Journal:  Ann Surg       Date:  2005-04       Impact factor: 12.969

Review 4.  Well-differentiated thyroid cancer.

Authors:  G H Jossart; O H Clark
Journal:  Curr Probl Surg       Date:  1994-12       Impact factor: 1.909

5.  Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation.

Authors:  Ozgur Mete; Sylvia L Asa
Journal:  Mod Pathol       Date:  2011-07-29       Impact factor: 7.842

6.  Follicular variant of papillary thyroid carcinoma: clinical-pathological characterization and long-term follow-up.

Authors:  Philippe Hagag; Nir Hod; Esther Kummer; Mehrzad Cohenpour; Tifha Horne; Mordechai Weiss
Journal:  Cancer J       Date:  2006 Jul-Aug       Impact factor: 3.360

7.  Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival.

Authors:  Jamal Zidan; Drumea Karen; Moshe Stein; Edward Rosenblatt; Walid Basher; Abraham Kuten
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

8.  Follicular variant of papillary thyroid carcinoma. A clinicopathologic study.

Authors:  E T Tielens; S I Sherman; R H Hruban; P W Ladenson
Journal:  Cancer       Date:  1994-01-15       Impact factor: 6.860

Review 9.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

10.  Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis.

Authors:  Ju-Han Lee; Eung-Seok Lee; Young-Sik Kim
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

View more
  7 in total

1.  Construction and investigation of lncRNA-associated ceRNA regulatory network in papillary thyroid cancer.

Authors:  Yangjing Zhao; Hui Wang; Chengjiang Wu; Meina Yan; Haojie Wu; Jingzhe Wang; Xinxin Yang; Qixiang Shao
Journal:  Oncol Rep       Date:  2018-01-10       Impact factor: 3.906

2.  Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases.

Authors:  Jingtai Zhi; Jingzhu Zhao; Ming Gao; Yi Pan; Jianghua Wu; Yigong Li; Dapeng Li; Yang Yu; Xiangqian Zheng
Journal:  Int J Clin Oncol       Date:  2017-07-25       Impact factor: 3.402

3.  Multiple metastasis of follicular variant of papillary thyroid carcinoma coexistent with malignant melanoma.

Authors:  Yu Ji Kim; Kyung Ae Lee; Tae Sun Park; Hong Sun Baek; Heung Yong Jin
Journal:  Korean J Intern Med       Date:  2017-01-16       Impact factor: 2.884

4.  The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting thezzm321990Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old

Authors:  Yasemin Giles Şenyürek; Yalın İşcan; İsmail Cem Sormaz; Şükran Poyrazoğlu; Fatih Tunca
Journal:  J Clin Res Pediatr Endocrinol       Date:  2022-02-09

5.  Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma.

Authors:  Fuxin Li; Wei Li; Katherine D Gray; Rasa Zarnegar; Dan Wang; Thomas J Fahey
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

6.  Identification of key candidate genes and pathways in follicular variant papillary thyroid carcinoma by integrated bioinformatical analysis.

Authors:  Lanyu Jing; Fada Xia; Xin Du; Bo Jiang; Yong Chen; Xinying Li
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

7.  Is a simplified TNM staging system more clinically relevant than the American Joint Committee on Cancer system for the follicular variant of papillary thyroid cancer?

Authors:  Di Hu; Yueye Huang; Wen Zeng; Sichao Chen; Yihui Huang; Man Li; Wei Long; Jianglong Huang; Wei Wei; Chao Zhang; Zeming Liu; Liang Guo
Journal:  Ann Transl Med       Date:  2020-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.